published meta-analysis   sensitivity analysis   studies

high-dose IFN beta-1a in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsDarazam, 2021 1.21 [0.65; 2.25] 1.21[0.65; 2.25]Darazam, 202110%168NAnot evaluable clinical improvementdetailed resultsDarazam, 2021 1.37 [0.88; 2.13] 1.37[0.88; 2.13]Darazam, 202110%168NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam, 2021 1.37 [0.88; 2.13] 1.37[0.88; 2.13]Darazam, 202110%168NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-27 20:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 904 - roots T: 290